Your browser doesn't support javascript.
loading
Immunodrugs: therapeutic VLP-based vaccines for chronic diseases.
Jennings, Gary T; Bachmann, Martin F.
Affiliation
  • Jennings GT; Cytos Biotechnology AG, Zurich-Schlieren 8952, Switzerland. gary.jennings@cytos.com
Annu Rev Pharmacol Toxicol ; 49: 303-26, 2009.
Article in En | MEDLINE | ID: mdl-18851703
ABSTRACT
Worldwide, the prevalence of noncommunicable chronic diseases is increasing. The use of vaccines to induce autoantibodies that neutralize disease-related proteins offers a means to effectively and affordably treat such diseases. Twenty vaccines designed to induce therapeutic autoantibodies were clinically tested in the past 12 years. Immunodrugs are therapeutic vaccines comprising virus-like particles (VLPs) covalently conjugated with self-antigens that induce neutralizing autoantibody responses. Four such VLP-based vaccines have been clinically tested and one has achieved proof of principle a reduction of blood pressure in hypertensive patients. To facilitate preliminary clinical testing, novel nonclinical study programs have been developed. Safety study designs have considered the underlying B and T cell immunology and have examined potential toxicities of vaccine components and primary and secondary pharmacodynamic action of the vaccines.
Subject(s)

Full text: 1 Database: MEDLINE Main subject: Virion / Vaccines / Chronic Disease / Immunotherapy Type of study: Risk_factors_studies Language: En Journal: Annu Rev Pharmacol Toxicol Year: 2009 Type: Article Affiliation country: Switzerland

Full text: 1 Database: MEDLINE Main subject: Virion / Vaccines / Chronic Disease / Immunotherapy Type of study: Risk_factors_studies Language: En Journal: Annu Rev Pharmacol Toxicol Year: 2009 Type: Article Affiliation country: Switzerland